CancerFax
ACCESS GUIDE Β· INDIA

HIFU IN
INDIA

India's top-tier hospitals offer HIFU with English-language care, JCI-accredited quality, and costs 65–75% below Western equivalents β€” making them an accessible option particularly for patients from South Asia, the Gulf, and East Africa who prefer shorter travel and familiar cultural environments.

analyticsAt a Glance

  • check_circleApollo Hospitals and Manipal Hospitals operate HIFU programmes for uterine fibroids and selected oncology indications
  • check_circleEnglish is the primary clinical language β€” no interpreter needed for South Asian patients
  • check_circleProcedure costs range from USD 2,500–6,000 for most HIFU indications β€” significantly below the West
  • check_circleE-visa for most South Asian, Middle Eastern, and East African nationals within 72 hours
Reviewed by: CancerFax Medical Team, Oncology & Haematology SpecialistsLast reviewed: June 4, 2026

India's HIFU Landscape: Growing Programme, English-Language Access

India's HIFU programme is younger and smaller in volume than China's β€” but it is rapidly maturing, particularly for uterine fibroid treatment where both MRgFUS and USgHIFU systems are now installed at major private hospital networks. For South Asian patients who prioritise English-language communication, shorter travel, and cultural familiarity over absolute programme volume, India offers a compelling alternative to China for appropriate HIFU indications.

β€œFor a woman from Bangladesh or Kenya with a symptomatic fibroid who speaks English and wants non-surgical treatment β€” India means a 3-hour flight, no interpreter, familiar food, and a HIFU result equivalent to what she would receive anywhere in the world.”
  • What India Does Well for HIFU

    English-language consultations, internationally trained specialists with UK and US fellowship experience, JCI-accredited hospital infrastructure, and a cost structure significantly below Western centres. India is particularly strong for uterine fibroid HIFU β€” a non-emergency elective procedure where quality of communication and patient comfort during a long treatment session matter greatly.

  • Where China Remains the Better Choice

    For oncology HIFU β€” liver cancer, pancreatic cancer, bone metastases, soft tissue tumours β€” China's HAIFU programme has substantially more volume, operator experience, and published evidence. Indian HIFU oncology programmes are developing but are not yet at the volume or specialisation level of China's top hepatology or oncology HIFU centres. For these indications, CancerFax will recommend China unless patient-specific factors make India more appropriate.

Leading Indian Centres for HIFU

The following hospitals have established HIFU programmes in India. CancerFax works with vetted institutions within this network for appropriate indications.

CentreCityHIFU SystemPrimary Indications
Apollo Hospitals (flagship sites)Chennai, Hyderabad, New DelhiUSgHIFU (HAIFU JC); MRgFUS (ExAblate at selected sites)Uterine fibroids (primary); selected liver and bone metastases
Manipal HospitalsBengaluru, MangaluruUSgHIFU (HAIFU)Uterine fibroids; selected abdominal oncology cases
Fortis Memorial Research InstituteGurugram (Delhi NCR)USgHIFUUterine fibroids; gynaecological HIFU; North India access point
Kokilaben Dhirubhai Ambani HospitalMumbaiUSgHIFU; MRgFUS at pilotUterine fibroids; integration with interventional oncology programme
KIMS HospitalsHyderabadUSgHIFU (HAIFU JC)Uterine fibroids; developing liver HIFU programme
Tata Memorial CentreMumbaiUSgHIFU (research and selected clinical)Selected oncology indications; institutional research programme; not routine clinical HIFU

HIFU Indications Available in India: A Practical Guide

Not all HIFU indications available in China are routinely performed at Indian centres. This table sets realistic expectations for what is accessible in India.

IndicationAvailability in IndiaRecommended DestinationNotes
Uterine fibroids (USgHIFU)Widely available β€” multiple centresIndia or China β€” both appropriateIndia preferred for English-speaking patients; comparable outcomes
Uterine fibroids (MRgFUS / ExAblate)Limited β€” selected centres onlyIndia (Apollo Chennai/Hyderabad) or Germany/UKConfirm ExAblate availability before travel; not all Apollo sites have MRgFUS
Liver cancer (HCC) β€” HIFULimited; developing programmeChina preferredChinese HAIFU centres have 10–20Γ— the liver HIFU volume of Indian centres
Pancreatic cancer β€” HIFUVery limited; specialist referralChina strongly preferredPancreatic HIFU requires specialist expertise not yet widely available in India
Bone metastases β€” HIFU pain palliationAvailable at selected centresIndia or China β€” both appropriateApollo and Fortis perform bone HIFU for palliative pain; outcomes comparable
Prostate cancer β€” HIFULimited; selected centresChina preferred for volumeFocal HIFU for prostate cancer requires high operator volume; China has more experienced operators
Thyroid nodules β€” HIFUAvailable at selected centresIndia appropriateThyroid HIFU is well-established at Apollo and Manipal for benign nodules

India vs China for HIFU: How to Choose

The right choice depends on indication, origin, language preferences, and the relative importance of programme volume versus access convenience.

India

  • English throughout β€” no interpreterAll clinical interactions in English β€” consultations, procedure day, and discharge discussions. Critical advantage for patients who value communication clarity.
  • Short travel for South Asian patientsBangladesh, Sri Lanka, Nepal, Kenya, Nigeria, and Gulf patients are 2–5 hours away β€” significantly less physical and logistical burden than a China trip.
  • Ideal for fibroid HIFU and benign indicationsFor elective, non-emergency HIFU β€” uterine fibroids, benign thyroid nodules β€” India's programme quality is fully appropriate and the patient experience advantages are real.
  • Familiar cultural environmentFood, support networks, and cultural norms are far more familiar for South Asian patients in India β€” important during a procedure that requires significant patient co-operation.

China

  • 10–20Γ— more oncology HIFU volumeFor liver, pancreatic, bone, and soft tissue HIFU, Chinese centres perform dramatically more procedures β€” operator experience accumulates proportionally.
  • Larger published evidence baseThe overwhelming majority of USgHIFU clinical evidence β€” particularly for oncology indications β€” comes from Chinese centres. India lacks this institutional research output for most HIFU oncology applications.
  • All indications availableEvery HIFU indication is available at Chinese centres β€” including complex and rare applications that are not yet routinely performed in India.
  • HAIFU original development and reference siteChongqing is the global reference centre for USgHIFU β€” for complex cases or second opinions on HIFU eligibility, Chinese centres have unmatched expertise.

India HIFU Access: Key Figures

Practical reference figures for international patients planning HIFU treatment in India.

  • USD 2,500–6,000Typical HIFU procedure cost in IndiaUterine fibroid HIFU at Apollo or Manipal: USD 2,500–4,500. Selected oncology HIFU: USD 3,500–6,000. Significantly below Western equivalents.
  • 72 hoursIndian medical e-visa processing timeMost South Asian, Gulf, and East African nationals qualify for the Indian medical e-visa, processed within 72 hours with a hospital invitation letter.
  • 5–8 daysTotal trip duration for fibroid HIFUPlanning assessment + 1–2 treatment sessions + recovery before return flight β€” most fibroid HIFU patients complete their India trip within a week.
  • 0Language barrier for English-speaking patientsAll clinical interactions at India's private hospital networks are conducted in English β€” no interpreter service required.

Frequently Asked Questions

Common questions from South Asian and international patients considering HIFU in India.

About HIFU in India

  • Can I get MRI-guided HIFU (ExAblate) for my fibroid in India?

    MRgFUS using the InSightec ExAblate system is available at selected Apollo Hospitals sites β€” the technology has been installed at flagship locations in Chennai and Hyderabad. However, not all Apollo sites have ExAblate, and availability changes. USgHIFU using the HAIFU system is more widely available across multiple Indian centres and achieves comparable fibroid treatment outcomes for the majority of eligible patients. CancerFax confirms current ExAblate availability at specific sites before recommending travel β€” and can advise whether your fibroid characteristics make MRgFUS specifically preferable to USgHIFU for your case.

  • I have liver cancer β€” should I choose India or China for HIFU?

    For liver cancer HIFU β€” particularly HCC or liver metastases β€” we would generally recommend China over India based on the volume differential. Chinese HAIFU centres, particularly Zhongshan Hospital and Chongqing, perform substantially more liver HIFU procedures annually than any Indian centre, have larger published outcome series, and have more developed sequential TACE + HIFU protocols. If travel to China is genuinely not possible for you β€” due to health, logistics, or family reasons β€” Indian HIFU for liver cancer can be arranged at appropriate centres, and CancerFax will identify the best available option. But for most patients, China is the stronger choice for oncology HIFU indications.

  • Is there a risk that HIFU is not available at the specific Indian hospital I'm referred to when I arrive?

    CancerFax confirms equipment operational status and specialist availability before any referral is made and before you book travel. Equipment downtime, operator absence, and scheduling gaps do occasionally occur at any centre globally β€” we build contingency into the timeline and maintain relationships with backup centres in the same city where possible. You will receive a written confirmation of your appointment and equipment status from the centre before departing for India. We do not send patients to a centre without this confirmation in place.

How CancerFax Helps

CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.

description
Medical Record Review

We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.

verified_user
Eligibility Coordination

We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.

hub
Hospital Communication

We support appointment coordination, document submission, translation, and direct communication with international departments.

flight
Travel & Admission Support

For international patients, we help with practical coordination β€” travel planning, hospital admission guidance, and local support.

explore
Treatment & Trial Navigation

If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.

support_agent
End-to-end Coordination

From inquiry through to follow-up, our coordinators provide a single point of contact for the family.

CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

Access HIFU in India Through CancerFax

CancerFax reviews your imaging and clinical history, identifies the most appropriate Indian HIFU centre for your indication, and manages consultation, hospital registration, and post-procedure follow-up β€” entirely in English, at no charge to you.

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.